NCT03064763 - Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

August 3, 2020

Study Completion Date

January 12, 2023

Conditions

Unresectable Stage IIIB-IV Malignant Melanoma

Interventions

DRUG

Talimogene laherparepvec

Talimogene laherparepvec will be administered as an intralesional injection.

Trial Locations (9)

Nagoya University Hospital, Nagoya

National Cancer Center Hospital East, Kashiwa-shi

Sapporo Medical University Hospital, Sapporo

Kumamoto University Hospital, Kumamoto

Shinshu University Hospital, Matsumoto-shi

Niigata Cancer Center Hospital, Niigata

Osaka International Cancer Institute, Osaka

Shizuoka Cancer Center, Sunto-gun

National Cancer Center Hospital, Chuo-ku